Bronchodilators, the most common type of asthma-fighting drug, inhibits contractions of airway smooth muscle that are induced by stimulating receptors on the muscle’s surface. New research highlights a novel mechanism for the drugs and will aid in the development of better medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The findings are detailed in a new article by researchers from Dundalk Institute of Technology in Ireland and Queen’s University in Northern Ireland.
Better Asthma and COPD Drugs with Fewer Side Effects Are Within Reach
Bronchodilators, the most common type of asthma-fighting drug, inhibits contractions of airway smooth muscle that are induced by stimulating receptors on the muscle's surface. New research highlights a novel mechanism for the drugs and will aid in the development of better medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The findings are detailed in a new article by researchers from Dundalk Institute of Technology in Ireland and Queen's University in Northern Ireland.